Loading...
Market
Academic Adoption Level of OpenCRISPR-1 by 2025
3
Resolution / Starting Odds
Low (0-10 institutions) • 25%
Moderate (11-30 institutions) • 25%
High (31-50 institutions) • 25%
Very High (over 50 institutions) • 25%
Academic publications, university press releases
Story
ProfluentBio Launches OpenCRISPR-1, First AI-Designed Open-Source Gene Editor
Apr 23, 2024, 01:49 AM
ProfluentBio has announced the successful deployment of the first ever AI-designed gene editor, OpenCRISPR-1, marking a significant advancement in genetic engineering. This innovative tool, developed using ProfluentBio's large language models, consists of a Cas9-like protein and guide RNA. The company has decided to freely release the molecules under the OpenCRISPR initiative, aiming to democratize access to cutting-edge gene editing capabilities and accelerate the development of personalized medicine. The release of OpenCRISPR-1 is expected to revolutionize the field of biomedicine by enabling more widespread and ethical use of CRISPR technologies. Coverage of this development has been provided by @nytimes, with further details available in an article by @cademetz.
View original story
Similar markets
Below 25% • 25%
25% to 50% • 25%
50% to 75% • 25%
Above 75% • 25%
Therapeutic applications • 25%
Research tools • 25%
Diagnostic tools • 25%
Personalized medicine • 25%
Widely adopted in tech industry • 33%
Limited adoption to specific sectors • 33%
Minimal adoption • 34%
Widely adopted • 33%
Moderately adopted • 33%
Poorly adopted • 33%
North America • 25%
Europe • 25%
Asia-Pacific • 25%
Rest of World • 25%
High adoption (>50% of Apple users) • 33%
Moderate adoption (20-50% of Apple users) • 33%
Low adoption (<20% of Apple users) • 34%
Widespread adoption • 33%
Moderate adoption • 33%
Low adoption • 34%
Highly positive (>75% approval) • 25%
Moderately positive (50-75% approval) • 25%
Neutral (25-50% approval) • 25%
Negative (<25% approval) • 25%